AMGNAmgen
$414.93+54% 1Y
$414.93
$265.4052 weeks$444.20
The financials
Amgen by the numbers
Amgen (AMGN) reported revenue of $10.1B in Q2 2026 (quarter ended Jun 30, 2026), up 9.5% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $2.38B (24% of revenue). For the full year FY2025, revenue was $36.8B (+10.0% year on year) and net income $7.71B. Its largest product in Q2 2026 was Other Products at $1.28B, 17% of the disclosed total, ahead of Enbrel at 7.6%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $10.1B | $9.18B | +9.5% |
| Gross profit | $7.24B | $6.17B | +17% |
| Operating income | $3.51B | $2.66B | +32% |
| Net income | $2.38B | $1.43B | +66% |
| Diluted EPS | $4.37 | $2.65 | +65% |
| Product | Revenue | Share |
|---|---|---|
| Other Products | $1.28B | 17% |
| Enbrel | $574M | 7.6% |
| EVENITY | $550M | 7.3% |
| TEPEZZA | $520M | 6.9% |
| Product And Service Other | $517M | 6.9% |
| Repathaevolocumab | $510M | 6.8% |
| TEZSPIRE | $486M | 6.5% |
| Prolia | $478M | 6.4% |
| Otezla | $431M | 5.7% |
| KRYSTEXXA | $399M | 5.3% |
| UPLIZNA | $317M | 4.2% |
| BLINCYTO | $285M | 3.8% |
| Nplate | $275M | 3.7% |
| IMDELLTRAIMDYLLTRA | $233M | 3.1% |
| Kyprolis | $201M | 2.7% |
| Xgeva | $187M | 2.5% |
| Vectibix | $167M | 2.2% |
| Aranesp | $94M | 1.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $7.51B (+22%)
UPLIZNA grew +140% year on yearXgeva -46% year on year
Segment Latestquarter on quarteryear on year
- Other Products$1.28B$1.28Bquarter on quarter +13%year on year +30%+13%+30%
- Enbrel$574.0M$574.0Mquarter on quarter +83%year on year -3.9%+83%-3.9%
- EVENITY$550.0M$550.0Mquarter on quarter +28%year on year +39%+28%+39%
- TEPEZZA$520.0M$520.0Mquarter on quarter +23%year on year +12%+23%+12%
- Product And Service Other$517.0M$517.0Mquarter on quarter +29%year on year +27%+29%+27%
- Repathaevolocumab$510.0M$510.0Mquarter on quarter +9.7%year on year +41%+9.7%+41%
- TEZSPIRE$486.0M$486.0Mquarter on quarter +42%year on year +42%+42%+42%
- Prolia$478.0M$478.0Mquarter on quarter +3.7%year on year -36%+3.7%-36%
- Otezla$431.0M$431.0Mquarter on quarter +22%year on year -16%+22%-16%
- KRYSTEXXA$399.0M$399.0Mquarter on quarter +56%year on year +14%+56%+14%
- UPLIZNA$317.0M$317.0Mquarter on quarter +29%year on year +140%+29%+140%
- BLINCYTO$285.0M$285.0Mquarter on quarter +29%year on year +5.6%+29%+5.6%
- Nplate$275.0M$275.0Mquarter on quarter -2.8%year on year +21%-2.8%+21%
- IMDELLTRAIMDYLLTRA$233.0M$233.0Mquarter on quarter +24%year on year +118%+24%+118%
- Kyprolis$201.0M$201.0Mquarter on quarter -7.8%year on year -13%-7.8%-13%
- Xgeva$187.0M$187.0Mquarter on quarter -18%year on year -46%-18%-46%
- Vectibix$167.0M$167.0Mquarter on quarter +23%year on year +16%+23%+16%
- Aranesp$94.0M$94.0Mquarter on quarter +22%year on year -12%+22%-12%
Drug Manufacturers, General
The closest names by size in the same industry